Cell Signaling Technology Logo
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CMTM6 (E6A8T) Rabbit mAb #90329

Filter:
  • WB
  • IP
  • IHC
  • IF

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 20-22
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100
    IHC Leica Bond 1:200 - 1:800
    Immunohistochemistry (Paraffin) 1:200 - 1:800
    Immunofluorescence (Frozen) 1:400 - 1:800
    Immunofluorescence (Immunocytochemistry) 1:400 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CMTM6 (E6A8T) Rabbit mAb recognizes endogenous levels of total CMTM6 protein. Staining of uncertain specificity was observed in human and mouse brain by immunohistochemistry. Non-specific nuclear staining was observed in mouse ovary by immunohistochemistry.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala176 of human CMTM6 protein.

    Background

    CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is a member of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (1). CMTM6 stabilizes plasma membrane expression of PD-L1, an immune inhibitory ligand critical for immune tolerance to self and anti-tumor immunity (2,3). CMTM6 associates with PD-L1 at recycling endosomes, where it protects PD-L1 from being targeted for lysosomal degradation by preventing STUB1-mediated PD-L1 ubiquitination (2,3). CMTM6 may stabilize PD-L1 expression on antigen presenting cells and potentiate inhibitory signaling by PD-1 on T cells, triggering T cell inhibition and exhaustion. CMTM6 has also been shown to interact with CD58, ARG1, ENO1, and TMPO (2). Due to the role of CMTM6 in regulating the immune system, it is being investigated as an immunotherapeutic target for the treatment of cancer.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.